| Identification | More | [Name]
Methylglucamine antimonate | [CAS]
133-51-7 | [Synonyms]
N-METHYL GLUCAMINE ANTIMONATE
N-METHYL GLUCAMINE ANTIMONIATE
1-deoxy-1-(methylamino)-,compd.withantimonicacid(1:1),d-glucito
1-deoxy-1-(methylamino)-d-glucitocompd.withantimonicacid(1:1)
1-deoxy-1-(methylamino)-d-glucitotrioxoantimonate(1-)
2168-rp
glucantime
meglumineantimonate
methylglucamineantimonate
protostib
1-deoxy-1-(methylamino)-D-glucitol, compound with antimonic acid (1:1)
N-METHYLGLUCAMINE ANTINMONIATE
N-MethylgluamineAntimoniate
MEGLUMINANTIMONIATE
N-METHYL GLUCAMINE ANTIMONIATE/MEGLUMINE ANTIMONIATE
1-Deoxy-1-(methylamino)-D-glucitol antimonate | [EINECS(EC#)]
205-108-3 | [Molecular Formula]
C7H20NO9Sb | [MDL Number]
MFCD01725422 | [Molecular Weight]
383.99 | [MOL File]
133-51-7.mol |
| Hazard Information | Back Directory | [Uses]
In the synthesis of surface active agents, pharmaceuticals, dyes. | [Pharmaceutical Applications]
N-Methylglucamine antimonate; methylaminoglucitol antimonate.
The SbV content varies around 28% between batches.
The major moieties are SbV–ligand complexes which are zwitterionic
in solution.
The activity, pharmacology and toxicology are similar to
those of sodium stibogluconate, with which it is essentially
interchangeable. | [Clinical Use]
Treatment of visceral and cutaneous leishmaniasis
Studies in Central and South America have indicated that the
combination with interferon-γ is effective in the treatment of
visceral and cutaneous leishmaniasis cases unresponsive to
antimony alone. |
|
|